Back to top
more

ASLAN Pharmaceuticals (ASLN)

(Delayed Data from NSDQ)

$2.47 USD

2.47
20,509

+0.18 (7.86%)

Updated Jul 11, 2024 03:52 PM ET

After-Market: $2.46 -0.01 (-0.40%) 7:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (70 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Rigel (RIGL) Up on FDA Nod to Blood Cancer Drug Rezlidhia

by Zacks Equity Research

The FDA approves Rigel's (RIGL) Rezlidhia (olutasidenib) for treating relapsed/refractory acute myeloid leukemia with a susceptible IDH1 mutation. Stock up.

BioNTech (BNTX) Inks Research Deal With Ryvu Therapeutics

by Zacks Equity Research

BioNTech (BNTX) signs a research collaboration agreement with Ryvu Therapeutics to develop small molecule programs targeting immune modulation in cancer and other diseases. Stock up.

Regeneron's (REGN) sBLA for Evkeeza Gets FDA Priority Review

by Zacks Equity Research

The FDA accepts for priority review Regeneron's (REGN) sBLA for Evkeeza for treating children aged five to 11 years with homozygous familial hypercholesterolemia. A decision is due on Mar 30, 2023.

Nabriva (NBRV) Posts Positive Data From Cystic Fibrosis Study

by Zacks Equity Research

Nabriva (NBRV) posts positive top-line data from the phase I study evaluating oral and intravenous Xenleta (lefamulin) in adult patients with cystic fibrosis. Shares down.

Axsome (AXSM) Gains as Alzheimer's Agitation Study Meets Goal

by Zacks Equity Research

Axsome's (AXSM) phase III ACCORD study evaluating AXS-05 for treating Alzheimer's disease agitation met the primary and key secondary endpoints. Shares rise.

Editas (EDIT) Declines More Than 30% in 3 Months: Here's Why

by Zacks Equity Research

Editas (EDIT) faces a major setback as it decides to pause enrollment in the phase I/II BRILLIANCE study on EDIT-101, treating Leber congenital amaurosis type 10.

Reasons to Add Immunovant (IMVT) Stock to Your Portfolio Now

by Zacks Equity Research

Immunovant (IMVT) is progressing well with its lead pipeline candidate batoclimab being developed for treating myasthenia gravis, thyroid eye disease and other autoimmune diseases.

Seagen (SGEN) Adcetris Label Expansion OK'd, New CEO Named

by Zacks Equity Research

The FDA approves Seagen's (SGEN) Adcetris for a new indication, treating pediatric patients with previously untreated high-risk Hodgkin lymphoma. The company also appoints a new CEO.

Kodiak Sciences' (KOD) Q3 Earnings Beat, Eye Candidate in Focus

by Zacks Equity Research

Kodiak Sciences (KOD) reports a narrower-than-expected loss for the third quarter of 2022. The focus is on the lead candidate, KSI-301, developed for treating various retinal vascular diseases.

Halozyme's (HALO) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Halozyme's (HALO) earnings and revenues beat estimates for the third quarter of 2022.

Apellis' (APLS) Q3 Earnings Miss Estimates, Revenues Top Mark

by Zacks Equity Research

Apellis' (APLS) earnings miss estimates in the third quarter of 2022 while revenues beat the same.

ASLAN (ASLN) Starts Phase IIb Study in Atopic Dermatitis

by Zacks Equity Research

ASLAN (ASLN) screens the first patient in the phase II dose ranging study evaluating its investigational monoclonal antibody in patients with atopic dermatitis.

Implied Volatility Surging for ASLAN Pharmaceuticals (ASLN) Stock Options

by Zacks Equity Research

Investors need to pay close attention to ASLAN Pharmaceuticals (ASLN) stock based on the movements in the options market lately.

New Strong Sell Stocks for June 8th

by Zacks Equity Research

ASLN, CANG, ESLT, GCI, and KRYS have been added to the Zacks Rank #5 (Strong Sell) List on June 8, 2021.

New Strong Sell Stocks for June 4th

by Zacks Equity Research

ASLN, BLRX, FLXN, ICMB, and MRNS have been added to the Zacks Rank #5 (Strong Sell) List on June 4, 2021.

Bayer's (BAYRY) Q1 Earnings & Revenues Surpass Estimates

by Zacks Equity Research

Bayer (BAYRY) beat estimates for earnings and revenues for the first quarter of 2021.

Kodiak Sciences (KOD) Q1 Earnings Miss, KSI-301 in Focus

by Zacks Equity Research

Kodiak Sciences (KOD) reports wider-than-expected loss for the first quarter of 2021. Pipeline development remains in focus for the company.

Catalyst (CPRX) Q1 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Catalyst's (CPRX) earnings beat estimates in the first quarter of 2021 while revenues missed the same.

Epizyme's (EPZM) Q1 Earnings Miss, Revenues Beat Estimates

by Zacks Equity Research

Epizyme (EPZM) reports wider-than-expected loss in the first quarter of 2021 despite its revenues beating estimates.

bluebird (BLUE) Q1 Loss Wider Than Expected, Revenues Beat

by Zacks Equity Research

bluebird (BLUE) reports a wider-than-expected loss for the first quarter of 2021 while revenues beat estimates.

Global Blood's (GBT) Q1 Earnings Miss, Revenues Rise Y/Y

by Zacks Equity Research

Global Blood (GBT) reports a wider-than-expected loss in the first quarter of 2021 and its revenues also miss estimates.

Horizon's (HZNP) Q1 Earnings Miss Estimates, Revenues Beat

by Zacks Equity Research

Horizon (HZNP) misses estimates for earnings in the first quarter of 2021 while revenues beat the same.

ACADIA (ACAD) Q1 Earnings Beat, Revenues Fall Shy of Estimates

by Zacks Equity Research

ACADIA's (ACAD) loss narrows in the first quarter of 2021 while its revenues miss the mark. Robust Nuplazid performance drives the top line year over year.

Editas (EDIT) Q1 Earnings Miss Estimates, Revenues Beat

by Zacks Equity Research

Editas (EDIT) reports wider-than-expected loss in the first quarter of 2021 while revenues beat estimates. Pipeline development remains in focus for the company.

BioMarin (BMRN) Q1 Earnings Beat, FDA Delays Vosoritide Decision

by Zacks Equity Research

BioMarin (BMRN) beats estimates for both earnings and revenues in the first quarter of 2021.